Stevanato Group Presents Vertiva™, a Versatile On-Body Delivery System Platform for a Wide Range of Injectable Therapies and for Large Delivery Volumes (up to 10mL)

Download as PDF

The Company offers the platform as a readily customizable pre-filled and pre-loaded on-body solution for drug delivery. Device development is making significant progress, with samples expected to be available in 2023

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva™, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005173/en/

Vertiva™ On-Body Delivery System (Photo: Business Wire)

Vertiva™ On-Body Delivery System (Photo: Business Wire)

Vertiva™’s unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL ISO cartridge, and a multi-use controller, offering potential sustainability and affordability benefits. These two parts communicate through a patented magnetically coupled drive mechanism. The device can adapt to different delivery profiles and can enable the administration of small-molecule drugs and biologics. Vertiva™ ‘s design is under development also to cover a broad range of volumes up to 10mL.

In the Vertiva™ device the cartridge is preloaded and sealed into the pod during factory assembly allowing the patient to benefit from simplified treatment initiation. Administrations can be conducted more comfortably at home, and the connectivity options of Vertiva™ can be ready for digital health applications. Upon treatment, the pod and controller can be more easily separated, and the controller can be reused, thereby reducing the environmental impact of electronic components.

Totally programmable to deliver micro-precision basal doses and full-content bolus injections, Vertiva™ is intended to be suitable for a wide range of therapies, such as cardiovascular and metabolic disorders, oncology, immunology, and pain diseases. Vertiva™ platform can also accommodate different customizations, including primary packaging format for larger injection volumes, delivery duration, and user interface.

The Vertiva™ brand name takes its cue from the word ‘versatility’ and suggests that the delivery profile is flexible, as it is programmable for basal and bolus delivery. The name also evokes ease of use for patients.

Stevanato Group will leverage the recently announced collaboration with Thermo Fisher Scientific to bring Vertiva™ to market. The platform will be offered as an integrated device and fill-and-finish solution to streamline the management of the pharmaceutical supply chain. The unparalleled combination of capabilities from two established industry providers can support pharma companies from drug development through to the final packaged product. Along with the proprietary device platform, Stevanato Group will offer its pre-sterilized EZ-fill® cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.

“The Vertiva™ on-body delivery system supports pharma companies in increasing the accessibility of in-home care and administered treatment options, which can ultimately lead to an improved patient experience,” said Steven Kaufman, VP for Drug Delivery Systems at Stevanato Group. “We are excited to be offering this device to the market, as it contributes to further strengthening our integrated capabilities in the drug delivery space. By utilizing a re-usable controller, we work towards greater sustainability and see cost benefits to our customers that use Vertiva™.”

Visit Stevanato Group’s website to learn more about Vertiva™ and request information on samples.

Forward-Looking Statements

This press release may include forward-looking statements. The words "making", “expected”, "to be", “intended”, “can”, “potential”, “will”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S. market, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: stevanatogroup.com

Media Stevanato Group
Stevanato Group: media@stevanatogroup.com
Cassie Gonzalez: stevanatoUS@teamlewis.com

Investor Relations Stevanato Group
Lisa Miles: lisa.miles@stevanatogroup.com

Source: Stevanato Group S.p.A.

Released June 12, 2023